BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...

The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...

The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...

The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...

Ultromics Ltd. received clearance from the U.S. FDA for Echogo Amyloidosis, its artificial intelligence-enhanced software that helps with the early diagnosis of cardiac amyloidosis, enabling timely ...

Monash University drug discovery researchers have found that a natural fat molecule called ‘lipoxin A4’ (LXA4) could significantly reduce inflammation and improve function for diabetic hearts.

Several case reports and retrospective cohort studies have described a marginal benefit with the use of internal cardioverter defibrillators in patients with cardiac amyloidosis. Detection of ...

View all available purchase options and get full access to this article. Department of Medicine, Columbia University Irving Medical Center/NewYork-Presbyterian ...

Amyloid fibrils appear in many neurodegenerative diseases, and scientists are eager to understand how they form and spread. But amyloids—clumped aggregations of misfolded proteins—can be ...

Cardiac amyloidosis is becoming increasingly recognized as an etiology for heart failure (HF). Most cases of amyloid cardiomyopathy will fall into one of two categories: light-chain amyloid (AL) ...

Endomyocardial biopsy is the only method by which the presence of cardiac amyloidosis can be directly established in cardiac amyloidosis, but this method is invasive, expensive and not always ...